Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan for Non-Small Cell Lung Cancer Therapy

Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 19 July 2018Source: Life SciencesAuthor(s): Mohammad Rasheduzzaman, Jae-Kyo Jeong, Sang-Youel ParkAbstractAimsTRAIL is a promising anticancer agent that has the potential to sensitize a wide variety of cancer or transformed cells by inducing apoptosis. However, resistance to TRAIL is a growing concern. Current manuscript aimed to employing combination treatment to investigate resveratrol induced TRAIL sensitization in NSCLC.MethodA549 and HCC-15 cells were used in experimental design. Cell viability was determined by morphological image, crystal violet staining and MTT assay. Apoptosis wa...
Source: Life Sciences - Category: Biology Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Conclusion: This article provides a brief current overview of literature pertaining to the role of radiation therapy in the management of lung cancer.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Conclusion: The approaches of this review are to highlight the recent management advances and contrast the differences of treatment practice between Western and Asian countries.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 April 2018Source: Respiratory InvestigationAuthor(s): Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi NakanishiAbstractInterstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung can...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Publication date: June 2018Source: Pathology - Research and Practice, Volume 214, Issue 6Author(s): Wei Gong, Yi Cao, Yuanyuan Wang, Lei Yang, Wenpeng Su, Fuman Qiu, Soham Datta, Boqi Rao, Jianfeng Xian, Mingzhu Lin, Yingyi Feng, Xin Zhang, Yifeng Zhou, Xingcheng Gao, Jiachun LuAbstractAntisense RNA (AS) is a type of long non-coding RNAs that functions as a post-transcriptional regulatory element on regulating parental coding gene expression via directly binding to complementary mRNA sequences. We aimed to investigate the effect of the AS to FEZF1 gene on non-small cell lung cancer (NSCLC) development. The expression level...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
ConclusionIt is recommended to consider baseline LCS scores while determining treatment strategies for older patients with advanced NSCLC.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Abstract Standard and targeted cancer therapies for late-stage cancer patients almost universally fail due to tumor heterogeneity/plasticity and intrinsic or acquired drug resistance. We used the telomerase substrate nucleoside precursor, 6-thio-2'-deoxyguanosine (6-thio-dG), to target telomerase-expressing non-small cell lung cancer cells resistant to EGFR-inhibitors and commonly used chemotherapy combinations. Colony formation assays, human xenografts as well as syngeneic and genetically engineered immune competent mouse models of lung cancer were used to test the effect of 6-thio-dG on targeted therapy- and che...
Source: Neoplasia - Category: Cancer & Oncology Authors: Tags: Neoplasia Source Type: research
Publication date: Available online 13 April 2018Source: Respiratory InvestigationAuthor(s): Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi NakanishiAbstractInterstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung can...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals